Buy Alembic Pharma; target of Rs 790: ICICI Direct
ICICI Direct is bullish on Alembic Pharma recommended buy rating on the stock with a target price of Rs 790 in its research report dated November 11, 2021.17-11-2021
17-11-2021
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited has received US Food and Drug Administration (USFDA) Final Approval for Mupirocin Cream USP, 2%. Please find enclosed herewith our press release. We request you to kindly take the same on record.17-11-2021
Hold Alembic Pharmaceuticals; target of Rs 778: KR Choksey
KR Choksey recommended hold rating on Alembic Pharmaceuticals with a target price of Rs 778 in its research report dated November 12, 2021.15-11-2021
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate(s) as per enclosed letter. We enclose herewith an e-mail intimation(s) received from Link lntime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.15-11-2021
Neutral Alembic Pharma; target of Rs 860: Motilal Oswal
Motilal Oswal recommended Neutral rating on Alembic Pharma with a target price of Rs 860 in its research report dated November 11, 2021.11-11-2021
Earnings Call for Q2FY22 of Alembic Pharmaceuticals
Conference Call with Alembic Pharmaceuticals Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.10-11-2021
ALEMBIC PHARMACEUTICALS LTD. - 533573 - USFDA Inspection At Alembic Pharmaceuticals Injectable Facility (F-3) At Karkhadi
We would like to inform that the United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals' Injectable Facility (F-3) located at Karkhadi from 28th October, 2021 to 10th November, 2021. The USFDA issued a Form 483 with 10 observations. None of the observations are related to data integrity and management believes that they are addressable. The Company is preparing the response to the observations, which will be submitted to the USFDA. The Company is committed to maintain the highest quality standards and compliance at all times. We request you to kindly take the same on record.10-11-2021
Q2FY22 Quarterly Result Announced for Alembic Pharmaceuticals Ltd.
Highlights: Net Profit Rs 169 crores Nel Sales for the quarter at Rs 1292 crores. Net Profit for the quarter at Rs 169 crores. Net sales for H-1 FY21 at Rs 2618 crores. Net profit for H-1 FY21 at Rs 334 crores. Mr. Shaunak Amin, Managing Director, Alembic Pharmacuticals Limited said "India Branded Formulation business has posted a. strong growth rate for the second consecutive quarter. This is attributed to the consistent efforts to redefine our business strategy and customer relationships, leading to a strong operational performance, along with a market outperforming growth across all our key product segments and therapy areas." Result PDF10-11-2021
Alembic Pharmaceuticals Ltd - 533573 - Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2021
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter and half year ended 30th September, 2021. The time of commencement of the Board Meeting was 12:20 p.m. and the time of conclusion was 1:45 p.m. We request you to kindly take the same on record.10-11-2021
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Outcome for Outcome Of Board Meeting
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter and half year ended 30th September, 2021. The time of commencement of the Board Meeting was 12:20 p.m. and the time of conclusion was 1:45 p.m. We request you to kindly take the same on record.10-11-2021